This season, 2020-2021 ARC offers the recombinant flu vaccine Flublok (QIV) instead of the High Dose Fluzone for our patients 65+. Both vaccines are made by Sanofi Pasteur and in efficacy tests comparing both to the standard dose (QIV) flu shot, Flublok (QIV) performed slightly better.
- Flublok (QIV) provided 30% better protection from influenza
- High Dose Fluzone (QIV) provided 24% better protection from influenza
Besides higher efficacy, ARC preferred Flublok this year because:
- It is available to people in more age categories than is High Dose Fluzone -- all patients 50+, and all patients 65+
- It does not contain antibiotics, eggs, thimerosal, preservatives, gelatin, or latex -- due to the unique manufacturing process of recombinant vaccines
Click here to read more about how flu vaccines are made.